CRA was retained in an international arbitration between two Japanese affiliates of multinational pharmaceutical companies. The dispute concerned Respondent’s performance under a co-promotion agreement. CRA’s team of life sciences consultants assessed indicators of commercially reasonable efforts using various industry data sources. The CRA team also quantified Claimant’s loss resulting from the alleged inadequate performance under the agreement, and responded to Respondent’s expert regarding damages alleged by Respondent.
2024 International Arbitration review: Updates and trends
Dear Clients and Friends, Our activities in 2024 reflected ongoing trends from 2023 and emerging forces affecting the landscape for investors and companies...